These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10147284)

  • 1. Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.
    Davey PG; Malek M
    Pharmacoeconomics; 1994; 5(Suppl 2):11-9. PubMed ID: 10147284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third generation cephalosporins in the parenteral to oral switch.
    Rimmer D
    Pharmacoeconomics; 1994; 5(Suppl 2):27-33. PubMed ID: 10147286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of cephalosporins for hospital formularies.
    Wilson WR
    Diagn Microbiol Infect Dis; 1995; 22(1-2):129-34. PubMed ID: 7587026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic considerations in the use of third-generation oral cephalosporins.
    Chambers ST; Murdoch DR; Pearce MJ
    Pharmacoeconomics; 1995 May; 7(5):416-27. PubMed ID: 10155329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomics of appropriate antimicrobial use.
    Davey P
    Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
    Starodubtseva OI; Vakhrushev IaM
    Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
    Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
    J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
    Wessels F; Anderson AN; Ebrahim O
    S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of pharmacoeconomics to the use of antibiotics.
    Eandi M; Zara GP; Della Pepa C
    Clin Microbiol Infect; 2000; 6 Suppl 3():90-2. PubMed ID: 11449665
    [No Abstract]   [Full Text] [Related]  

  • 13. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins.
    Tice AD
    Drugs; 2000; 59 Suppl 3():29-35; discussion 47-9. PubMed ID: 10845411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of antibiotic usage].
    Balpataki R; Balogh J; Zelkó R; Vincze Z
    Acta Pharm Hung; 2001; 71(1):108-13. PubMed ID: 11769090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model to transfer trial-based pharmacoeconomic analyses to clinical practice.
    Gandjour A
    Pharmacoeconomics; 2011 Feb; 29(2):97-105. PubMed ID: 21244101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefuroxime axetil: an updated review of its use in the management of bacterial infections.
    Scott LJ; Ormrod D; Goa KL
    Drugs; 2001; 61(10):1455-500. PubMed ID: 11558834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fourth generation cephalosporins in treating severe hospital infections: pharmacoeconomic aspects].
    Rudakova AV
    Antibiot Khimioter; 2001; 46(9):33-9. PubMed ID: 11871014
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.